Live Chat ×
Skip to main content

Updates from the New WHO Classification of Soft Tissue and Bone Tumors



Original release date:
 April 1, 2020
Access to this course expires on: December 6, 2022 at 11:59 PM Pacific Time
CME/SAMs 12.25

Course Description

The diagnosis of soft tissue and bone tumors can be a significant challenge, even to the experienced surgical pathologist, due to the rarity of such tumors, the broad morphological spectrum of mesenchymal neoplasms, and overlap with other soft tissue and bone tumors and non-mesenchymal neoplasms. The classification of soft tissue and bone tumors continues to evolve, following the description of "new" tumor types, the discovery of novel molecular genetic alterations, and the development of increasingly specific diagnostic immunohistochemical markers; these changes are included in the new World Health Organization (WHO) Classification of Tumours of Soft Tissue and Bone. Surgical pathologists are not familiar with the current classification of soft tissue and bone tumors and recently developed diagnostic markers and struggle with accurate diagnosis. This course, presented by experts, will help to alleviate that struggle and provide pragmatic information for immediate practice improvement.

Target Audience
Practicing academic and community pathologists, and pathologists-in-training

Learning Objectives
Upon completion of this educational activity, learners will be able to:
  • Review update in soft tissue and bone tumors based on the new WHO classification
  • Apply recently developed immunohistochemical markers for the diagnosis of soft tissue and bone tumors
  • Understand the role of recently identified molecular genetic alterations in the diagnosis of soft tissue and bone tumors

Continuing Medical Education and Continuing Certification
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 12.25  AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

USCAP is approved by the American Board of Pathology (ABPath) to offer Self-Assessment credits (SAMs) and Lifelong Learning (Part II) credit for the purpose of meeting the ABPath requirements for Continuing Certification (CC).

Physicians can earn a maximum of 12.25 SAM/Part II credit hours.

Disclosures
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships: Jason L. Hornick, MD, PhD, Consultant, Eli Lilly, Epizyme; Jessica L. Davis, MD, Consultant, Bayer Pharmaceuticals

The following faculty reported no relevant financial relationships: G. Petur Nielsen, MD, Khin Thway, MD, FRCPath

The following IM Coordinator who planned and reviewed content for this activity reported no relevant financial relationships: Steven D. Billings, MD

USCAP staff associated with the development of content for this activity reported no relevant financial relationships.

To earn CME and SAM credit, all learners must complete the evaluation. Your certificate will be available to view and print by  clicking here.

Buy the entire Updates from the New WHO Classification of Soft Tissue and Bone Tumors course and get a great discount!

Not A Member?  Click Here